Letermovir

• Description :

  Letermovir (AIC246) is a potent inhibitor of CMV, which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.

• Product Name Alternative :

  AIC246; MK-8228

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  CMV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/letermovir.html

• Purity :

  99.96

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1

• Molecular Formula :

  C29H28F4N4O4

• Molecular Weight :

  572.55

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56 (2) :1135-7.|[2]Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85 (20) :10884-93.|[3]Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1290-7.|[4]Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59 (6) :3140-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [917389-32-3]